1. Home
  2. VIR vs BFS Comparison

VIR vs BFS Comparison

Compare VIR & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • BFS
  • Stock Information
  • Founded
  • VIR 2016
  • BFS 1993
  • Country
  • VIR United States
  • BFS United States
  • Employees
  • VIR N/A
  • BFS N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • BFS Real Estate Investment Trusts
  • Sector
  • VIR Health Care
  • BFS Real Estate
  • Exchange
  • VIR Nasdaq
  • BFS Nasdaq
  • Market Cap
  • VIR 844.9M
  • BFS 830.6M
  • IPO Year
  • VIR 2019
  • BFS 1993
  • Fundamental
  • Price
  • VIR $5.43
  • BFS $35.13
  • Analyst Decision
  • VIR Strong Buy
  • BFS Strong Buy
  • Analyst Count
  • VIR 7
  • BFS 1
  • Target Price
  • VIR $32.86
  • BFS $45.50
  • AVG Volume (30 Days)
  • VIR 1.1M
  • BFS 66.5K
  • Earning Date
  • VIR 07-31-2025
  • BFS 07-31-2025
  • Dividend Yield
  • VIR N/A
  • BFS 6.71%
  • EPS Growth
  • VIR N/A
  • BFS N/A
  • EPS
  • VIR N/A
  • BFS 1.47
  • Revenue
  • VIR $20,861,000.00
  • BFS $274,011,000.00
  • Revenue This Year
  • VIR N/A
  • BFS $7.78
  • Revenue Next Year
  • VIR N/A
  • BFS $6.78
  • P/E Ratio
  • VIR N/A
  • BFS $23.61
  • Revenue Growth
  • VIR N/A
  • BFS 5.04
  • 52 Week Low
  • VIR $4.32
  • BFS $31.25
  • 52 Week High
  • VIR $14.45
  • BFS $42.39
  • Technical
  • Relative Strength Index (RSI)
  • VIR 56.02
  • BFS 57.44
  • Support Level
  • VIR $4.91
  • BFS $33.50
  • Resistance Level
  • VIR $5.35
  • BFS $34.69
  • Average True Range (ATR)
  • VIR 0.26
  • BFS 0.85
  • MACD
  • VIR 0.02
  • BFS -0.02
  • Stochastic Oscillator
  • VIR 98.11
  • BFS 83.16

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

Share on Social Networks: